Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 4/20 | 0.39 |
| ▸ | METAP1 | P53582 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21086903 | 0.89 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19HTTMETAP2 | |
| SCHEMBL21086900 | 0.86 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19HTTMETAP2 | |
| SCHEMBL19924329 | 0.80 | CYP1A2 (0.45) | CYP1A2CYP2C9CYP2C19HTTMETAP2 | |
| SCHEMBL16626925 | 0.68 | CYP1A2 (0.64) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL7615739 | 0.68 | METAP2 (0.55) | CYP1A2CYP2C9CYP2C19HTTMETAP2 | |
| SCHEMBL3765470 | 0.68 | METAP2 (0.55) | CYP1A2CYP2C9CYP2C19HTTMETAP2 | |
| SCHEMBL19924408 | 0.67 | METAP2 (0.41) | CYP1A2CYP2C9CYP2C19HTTMETAP2 | |
| SCHEMBL12438545 | 0.67 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2953811 | 0.67 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2953807 | 0.67 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20190177355-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177355-A1 | COMPOSITIONS COMPRISING REVERSIBLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | GSS, GSR, RNMT | CYP1A2 4654/4885CYP2C9 3232/4885CYP2C19 4121/4885 |
| US-12037358-B2 | Compositions comprising reversibly modified oligonucleotides and uses thereof | GSS, GSR, RNMT | CYP1A2 4654/4885CYP2C9 3232/4885CYP2C19 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.